EOLS - Evolus, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.74
+1.08 (+7.91%)
At close: 4:00PM EST

14.74 0.00 (0.00%)
After hours: 4:42PM EST

Stock chart is not supported by your current browser
Previous Close13.66
Open13.68
Bid10.00 x 800
Ask15.94 x 900
Day's Range13.68 - 14.78
52 Week Range6.75 - 39.50
Volume143,286
Avg. Volume355,747
Market Cap402.034M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.50
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Evolus Reports Third Quarter 2018 Financial Results

    - Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET - IRVINE, Calif.,.

  • GlobeNewswire15 days ago

    Evolus to Participate in Two Upcoming Investor Conferences

    IRVINE, Calif., Nov. 01, 2018 -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in two.

  • GlobeNewswire24 days ago

    Evolus Expands Leadership Team with Appointments of Key Executives

    Evolus, Inc. (EOLS), a company dedicated to aesthetic medicine, today announced the expansion of its leadership team with the appointments of three key executives reporting to David Moatazedi, President and Chief Executive Officer. Evolus has appointed Kurt Knab as Vice President of Sales, Alejandro “Alex” Sabad as Vice President of Operations and Amy Marinne Fox as Vice President of Human Resources.

  • GlobeNewswire25 days ago

    Detailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare, and Frontline — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.27 days ago

    What Kind Of Shareholder Owns Most Evolus Inc (NASDAQ:EOLS) Stock?

    If you want to know who really controls Evolus Inc (NASDAQ:EOLS), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • GlobeNewswire29 days ago

    Evolus to Release Third Quarter 2018 Financial Results on Monday, November 5, 2018

    IRVINE, Calif., Oct. 18, 2018 -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that it will release 2018 third quarter financial.

  • GlobeNewswire2 months ago

    Evolus to Present at the Cantor Global Healthcare Conference

    IRVINE, Calif., Sept. 20, 2018-- Evolus, Inc., a company dedicated to aesthetic medicine, announced today that members of management will present at the Cantor Global Healthcare Conference in New York, ...

  • GlobeNewswire2 months ago

    Evolus Appoints Ashwin K. Agarwal as Vice President, Finance, Investor Relations and Treasury

    Evolus, Inc. (EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Ashwin K. Agarwal as Vice President, Finance, Investor Relations, and Treasury, effective immediately. Mr. Agarwal joins Evolus from Alder BioPharmaceuticals where he served as Vice President, Corporate Strategy and brings with him over 20 years of both operational and corporate finance, investor relations, and accounting experience, from his time at both early and late stage healthcare companies. Earlier in his career, Mr. Agarwal served as Vice President, Finance and Investor Relations at a medical aesthetics start-up and also held roles of increasing responsibility at Allergan for fifteen years, most recently as Senior Director of Finance and Investor Relations.

  • GlobeNewswire3 months ago

    Evolus Receives Acceptance of FDA BLA Resubmission for DWP-450

    Evolus, Inc. (EOLS), a company dedicated to aesthetic medicine, today announced the acceptance of its resubmission of its Biologics License Application for its lead product candidate, prabotulinumtoxinA (DWP-450), by the U.S. Food and Drug Administration (“FDA”). The FDA considered the resubmission a Class 2 response and has assigned a February 2, 2019 action date per the Prescription Drug User Fee Act (PDUFA).

  • Maker of Botox Rival Soars as Treatment May Win Approval By Spring
    Bloomberg3 months ago

    Maker of Botox Rival Soars as Treatment May Win Approval By Spring

    The first new aesthetic neurotoxin to rival Allergan Plc’s Botox in almost a decade may be approved in time for Valentine’s Day. Evolus Inc. Chief Executive Officer David Moatazedi says his company remains on track for a spring 2019 launch for its experimental wrinkle treatment, DWP-450. The Food and Drug Administration is now expected to make a decision on the drug by February 2 after the company failed to secure approval in May when the agency had questions on the company’s chemistry, manufacturing and controls processes.

  • ACCESSWIRE4 months ago

    Free Technical Research on Evolus and Three More Generic Drugs Equities

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on EOLS sign up now at www.wallstequities.com/registration. On Tuesday, July 24, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.79% and 0.48% higher, respectively at the closing bell, while the NASDAQ Composite stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drugs - Generic equities this morning: Evolus Inc. (EOLS), Fibrocell Science Inc. (NASDAQ: FCSC), Flexion Therapeutics, Inc. (NASDAQ: FLXN), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA).

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Investopedia4 months ago

    6 IPOs Bringing Rich Profits To Stock Investors

    The market for initial public offerings (IPOs) of stock in the U.S. has been been hotter than a firecracker in 2018. In the first half of the year, 120 companies have gone public in the U.S., raising $35.2 billion in the process, according to data from Dealogic  cited by The Wall Street Journal. IPOs brought to market so far in 2018 have produced an average gain of 22% for investors, per the Journal.